{
  "id": "5a70e4b399e2c3af26000008",
  "type": "factoid",
  "question": "Glecaprevir and Pibrentasvir are used for tratment of which disease?",
  "ideal_answer": "The combination of direct-acting antivirals glecaprevir and pibrentasvir is effective for treatment of Hepatitis C virus infection.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
    "http://www.ncbi.nlm.nih.gov/pubmed/28951228",
    "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
    "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
    "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
    "http://www.ncbi.nlm.nih.gov/pubmed/28480743",
    "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
    "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
    "http://www.ncbi.nlm.nih.gov/pubmed/28688001"
  ],
  "snippets": [
    {
      "text": "Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) \u00b1 ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations.LAY SUMMARY: The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND AND OBJECTIVE</b>: Glecaprevir and pibrentasvir are pangenotypic direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVE: Glecaprevir and pibrentasvir are pangenotypic direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four patients discontinued the trial treatment prematurely because of adverse events; three of these patients had a sustained virologic response.<br><b>CONCLUSIONS</b>: Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the safety and efficacy of 8 and 12 weeks' treatment with glecaprevir/pibrentasvir in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis in 3 separate phase 3 trials.<br><b>METHODS</b>: We performed 2 open label, single-arm studies (SURVEYOR-II, Part 4 and ENDURANCE-4) and a randomized, double-blind, placebo-controlled study (ENDURANCE-2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951228",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among patients receiving glecaprevir/pibrentasvir for 12 weeks, rates of SVR12 were 99.5% (95% CI, 98.5-100) in those infected with HCV genotype 2 and 99% (95% CI, 97.6-100) in those infected with HCV genotype 4, 5, or 6.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951228",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Coadministration of glecaprevir 400\u00a0mg increased pibrentasvir 120 and 40\u00a0mg steady-state C and AUC values to 2.9-6.3-fold, and coadministration of glecaprevir 700\u00a0mg increased pibrentasvir 160\u00a0mg steady-state C and AUC values to up to sevenfold of the values when pibrentasvir was administered alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Hepatitis C virus infection"
}